奥精医疗科技股份有限公司2025年度业绩快报公告

Core Viewpoint - The company reported a significant increase in revenue and net profit for the year 2025, driven by strategic market initiatives and operational improvements [1][3]. Financial Performance - The company achieved total revenue of 223.51 million yuan, representing a year-on-year growth of 8.48% [1]. - The net profit attributable to the parent company was 13.15 million yuan, showing a remarkable increase of 203.86% compared to the previous year [1]. - Total assets at the end of the reporting period were 1.564 billion yuan, reflecting a growth of 1.64% from the beginning of the year [2]. - The equity attributable to the parent company was 1.433 billion yuan, up by 2.21% from the start of the year [2]. - The net asset value per share attributable to the parent company was 10.47 yuan, an increase of 1.13% [2]. Operational Factors - The orthopedic artificial bone procurement provided opportunities for continued clinical usage and market share expansion, prompting the company to enhance its production assurance system [3]. - The company implemented a refined regional market strategy and precise marketing tactics to broaden its sales network, contributing to steady revenue growth and reinforcing its leading position in niche markets [3]. - The increase in operating profit, total profit, and net profit attributable to the parent company exceeded 30%, primarily due to the procurement initiative and the recovery of long-term accounts receivable, which significantly reduced credit impairment losses [4].